These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 21852251)

  • 1. Post-marketing surveillance (PMS) of all patients treated with irinotecan in Japan: clinical experience and ADR profile of 13,935 patients.
    Tadokoro J; Kakihata K; Shimazaki M; Shiozawa T; Masatani S; Yamaguchi F; Sakata Y; Ariyoshi Y; Fukuoka M
    Jpn J Clin Oncol; 2011 Sep; 41(9):1101-11. PubMed ID: 21852251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy: a postmarketing survey.
    Shiozawa T; Tadokoro J; Fujiki T; Fujino K; Kakihata K; Masatani S; Morita S; Gemma A; Boku N
    Jpn J Clin Oncol; 2013 May; 43(5):483-91. PubMed ID: 23536639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pilot study of irinotecan in refractory small cell lung cancer].
    Fujita A; Takabatake H; Tagaki S; Sekine K
    Gan To Kagaku Ryoho; 1995 Jun; 22(7):889-93. PubMed ID: 7793995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
    Soepenberg O; Dumez H; Verweij J; de Jong FA; de Jonge MJ; Thomas J; Eskens FA; van Schaik RH; Selleslach J; Ter Steeg J; Lefebvre P; Assadourian S; Sanderink GJ; Sparreboom A; van Oosterom AT
    Clin Cancer Res; 2005 Feb; 11(4):1504-11. PubMed ID: 15746053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Kampo medicines for the prevention of irinotecan-induced diarrhea in advanced non-small cell lung cancer].
    Mori K; Hirose T; Machida S; Tominaga K
    Gan To Kagaku Ryoho; 1998 Jul; 25(8):1159-63. PubMed ID: 9679578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Irinotecan in small-cell lung cancer.
    Ando Y; Figg WD
    N Engl J Med; 2002 May; 346(18):1414-5; author reply 1414-5. PubMed ID: 11986422
    [No Abstract]   [Full Text] [Related]  

  • 7. [Clinical evaluation of irinotecan combined with cisplatin by divided administration in patients with untreated primary non-small cell lung cancer].
    Asano T; Namikawa O; Yamamoto A; Sano T; Mukai J; Kawaji K; Kobayashi M
    Nihon Kokyuki Gakkai Zasshi; 1998 Sep; 36(9):771-5. PubMed ID: 9866979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irinotecan hydrochloride for the treatment of recurrent and refractory non-Hodgkin lymphoma: a single institution experience.
    Sugiyama K; Omachi K; Fujiwara K; Saotome T; Mizunuma N; Takahashi S; Ito Y; Aiba K; Horikoshi N
    Cancer; 2002 Feb; 94(3):594-600. PubMed ID: 11857289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Irinotecan-containing combinations in solid tumors, except colonic carcinomas].
    Couteau C; Armand JP
    Bull Cancer; 1998 Dec; Spec No():47-50. PubMed ID: 9932085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of irinotecan as a third- or fourth-line treatment for advanced non-small cell lung cancer: NJLCG0703.
    Matsubara N; Maemondo M; Inoue A; Ishimoto O; Watanabe K; Sakakibara T; Fukuhara T; Morikawa N; Tanaka M; Sugawara S; Nukiwa T
    Respir Investig; 2013 Mar; 51(1):28-34. PubMed ID: 23561256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A).
    Fukuda M; Shimada M; Kitazaki T; Nagashima S; Hashiguchi K; Ebi N; Takayama K; Nakanishi Y; Semba H; Harada T; Seto T; Okamoto I; Ichinose Y; Sugio K
    Thorac Cancer; 2017 Jan; 8(1):40-45. PubMed ID: 27883280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Examination of UGT1A1 polymorphisms and irinotecan-induced neutropenia in patients with Colorectal cancer].
    Teruya T; Nakachi A; Shimabukuro N; Toritsuka D; Azuma Y; Hanashiro K; Nishiki T; Ota M; Shimabuku M; Shiroma H
    Gan To Kagaku Ryoho; 2015 May; 42(5):585-9. PubMed ID: 25981652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion.
    Ohe Y; Sasaki Y; Shinkai T; Eguchi K; Tamura T; Kojima A; Kunikane H; Okamoto H; Karato A; Ohmatsu H
    J Natl Cancer Inst; 1992 Jun; 84(12):972-4. PubMed ID: 1321253
    [No Abstract]   [Full Text] [Related]  

  • 14. A risk-benefit assessment of irinotecan in solid tumours.
    Siu LL; Rowinsky EK
    Drug Saf; 1998 Jun; 18(6):395-417. PubMed ID: 9638386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study.
    Ueoka H; Tabata M; Kiura K; Shibayama T; Gemba K; Segawa Y; Chikamori K; Yonei T; Hiraki S; Harada M
    Br J Cancer; 1999 Feb; 79(5-6):984-90. PubMed ID: 10070901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of cisplatin and irinotecan as induction chemotherapy followed by concomitant thoracic radiotherapy with weekly low-dose irinotecan in unresectable, stage III, non-small cell lung cancer: JCOG 9706.
    Takeda K; Negoro S; Tanaka M; Fukuda H; Nakagawa K; Kawahara M; Semba H; Kudoh S; Sawa T; Saijo N; Fukuoka M
    Jpn J Clin Oncol; 2011 Jan; 41(1):25-31. PubMed ID: 20802006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
    Rothenberg ML; Cox JV; DeVore RF; Hainsworth JD; Pazdur R; Rivkin SE; Macdonald JS; Geyer CE; Sandbach J; Wolf DL; Mohrland JS; Elfring GL; Miller LL; Von Hoff DD
    Cancer; 1999 Feb; 85(4):786-95. PubMed ID: 10091755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
    Rowinsky EK; Grochow LB; Ettinger DS; Sartorius SE; Lubejko BG; Chen TL; Rock MK; Donehower RC
    Cancer Res; 1994 Jan; 54(2):427-36. PubMed ID: 8275479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.
    de Jong FA; Kehrer DF; Mathijssen RH; Creemers GJ; de Bruijn P; van Schaik RH; Planting AS; van der Gaast A; Eskens FA; Janssen JT; Ruit JB; Verweij J; Sparreboom A; de Jonge MJ
    Oncologist; 2006 Sep; 11(8):944-54. PubMed ID: 16951398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical activity spectrum of irinotecan].
    Cottu PH; Extra JM; Lerebours F; Espie M; Marty M
    Bull Cancer; 1998 Dec; Spec No():21-5. PubMed ID: 9932080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.